About Gregory

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has developed extensive national and international collaborations, and is internationally recognized in the areas of HCV natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.

Professor Dore established the St Vincent’s Hospital viral hepatitis service in 1999, and has led its development into one of the leading national and international hepatitis C treatment services, with a particular focus on marginalised populations including people who inject drugs and homeless persons.

This speaker will be presenting at the following session(s)

  • Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity

    Golden Hall

    Day: 2 November

    Time: 09:15

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".

    Chairs: Dr. Florence Zeh Kakanou, Ministry of Public Health, Cameroon and Dr. Saeed Hamid, The Aga Khan University, Pakistan

    Presentations:

    • 5 core interventions to reach HBV and HCV elimination.
      Dr. Hande Harmanci, World Health Organization

    Panel:

    • Hepatitis B services – challenges and opportunities.
      Dr. Chukwuma Anyaike, Federal Ministry of Health, Nigeria
    • Hepatitis B vaccines: a won battle or still more to do?
    • Hepatitis C prevention and treatment for PWID.
      Prof. Gregory Dore, Kirby Institute, UNSW Sydney and St Vincent’s Hospital, Sydney
    • Hepatitis services for indigenous people.
      Luana Silveira de Faria, Ministry of Health, Brazil
    • Q & A session.

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.
  • Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity

    Golden Hall

    Day: 2 November

    Time: 09:15

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".

    Chairs: Dr. Florence Zeh Kakanou, Ministry of Public Health, Cameroon and Dr. Saeed Hamid, The Aga Khan University, Pakistan

    Presentations:

    • 5 core interventions to reach HBV and HCV elimination.
      Dr. Hande Harmanci, World Health Organization

    Panel:

    • Hepatitis B services – challenges and opportunities.
      Dr. Chukwuma Anyaike, Federal Ministry of Health, Nigeria
    • Hepatitis B vaccines: a won battle or still more to do?
    • Hepatitis C prevention and treatment for PWID.
      Prof. Gregory Dore, Kirby Institute, UNSW Sydney and St Vincent’s Hospital, Sydney
    • Hepatitis services for indigenous people.
      Luana Silveira de Faria, Ministry of Health, Brazil
    • Q & A session.

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.